Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification

Cellular Oncology

Volumn 37, Issue 2, 2014, Pages 107-118

  Tabarestani, Sanaz ^a   Ghaderian, Sayyed Mohammad Hossein ^b   Rezvani, Hamid ^c   Mirfakhraie, Reza ^a   Ebrahimi, Abdolali ^c   Attarian, Hamid ^c   Rafat, Jahangir ^d   Ghadyani, Mojtaba ^c   Alavi, Hossein Afshin ^e   Kamalian, Naser ^f   Rakhsha, Afshin ^g   Azargashb, Eznollah ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e Day Hospital   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Copy number alterations; MLPA; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; CCND1 PROTEIN, HUMAN; CYCLIN D1; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CCND1 GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE LOSS; HUMAN; MAJOR CLINICAL STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PREDICTIVE VALUE; PRIORITY JOURNAL; TOP2A GENE; TUMOR INVASION; TUMOR VOLUME; ADULT; AGED; BREAST NEOPLASMS; CASE CONTROL STUDY; DRUG EFFECTS; GENETICS; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLIN D1; DNA COPY NUMBER VARIATIONS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; HUMANS; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84899629390     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-013-0165-1     Document Type: Article

References (63)

1. M.H. Forouzanfar, K.J. Foreman, A.M. Delossantos, R. Lozano, A.D. Lopez, C.J. Murray et al., Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378, 1461-1484 (2011)
2. J.M. Harvey, G.M. Clark, C.K. Osborne, D.C. Allred, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17, 1474-1481 (1999)
3. E.V. Jensen, V.C. Jordan, The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 9, 1980-1989 (2003)
4. Early Breast Cancer Trialists' Collaborative Group, C. Davies, J. Godwin, R. Gray, M. Clarke, D. Cutter et al., Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771-784 (2011)
5. Early Breast Cancer Trialists' Collaborative Group, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005)
6. A. Ring, M. Dowsett, Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11, 643-658 (2004)
7. M.D. Pegram, G. Pauletti, D.J. Slamon, HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52, 65-77 (1998)
8. J.S. Ross, J.A. Fletcher, The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3, 237-252 (1998)
9. F. Holst, C.B. Moelans, M. Filipits, C.F. Singer, R. Simon, P.J. van Diest, On the evidence for ESR1 amplification in breast cancer. Nat. Rev. Cancer 12, 149 (2012)
10. K. Park, S. Han, E. Shin, H.J. Kim, J.Y. Kim, EGFR gene and protein expression in breast cancers. Eur. J. Surg. Oncol. 33, 956-960 (2007)
11. S.L. Deming, S.J. Nass, R.B. Dickson, B.J. Trock, C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br. J. Cancer 83, 1688-1695 (2000)
12. K. Al-Kuraya, P. Schraml, J. Torhorst, C. Tapia, B. Zaharieva, H. Novotny et al., Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 64, 8534-8540 (2004)
13. K. Holm, J. Staaf, G. Jonsson, J. Vallon-Christersson, H. Gunnarsson, A. Arason et al., Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours. Breast Cancer Res. Treat. 133, 583-594 (2012)
14. K.V. Nielsen, B. Ejlertsen, S. Moller, J.T. Jorgensen, A. Knoop, H. Knudsen et al., The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol. 47, 725-734 (2008)
15. N. Turner, A. Pearson, R. Sharpe, M. Lambros, F. Geyer, M.A. Lopez-Garcia et al., FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70, 2085-2094 (2010)
16. I.J. Chalmers, M. Aubele, E. Hartmann, E. Braungart, M. Werner, H. Hofler et al., Mapping the chromosome 16 cadherin gene cluster to a minimal deleted region in ductal breast cancer. Cancer Genet. Cytogenet. 126, 39-44 (2001)
17. K. Lundgren, K. Holm, B. Nordenskjold, A. Borg, G. Landberg, Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res. 10, R81 (2008)
18. K. Jirstrom, M. Stendahl, L. Ryden, A. Kronblad, P.O. Bendahl, O. Stal et al., Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res. 65, 8009-8016 (2005)
19. K. Lundgren, M. Brown, S. Pineda, J. Cuzick, J. Salter, L. Zabaglo et al., Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res. 14, R57 (2012)
20. E.M. Berns, J.A. Foekens, I.L. van Staveren, W.L. van Putten, H.Y. de Koning, H. Portengen et al., Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159, 11-18 (1995)
21. J.P. Schouten, C.J. McElgunn, R. Waaijer, D. Zwijnenburg, F. Diepvens, G. Pals, Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 30, e57 (2002)
22. C.B. Moelans, R.A. de Weger, M.T. van Blokland, C. Ezendam, S. Elshof, M.G. Tilanus et al., HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cell. Oncol. 31, 1-10 (2009)
23. C.B. Moelans, R.A. de Weger, H.N. Monsuur, R. Vijzelaar, P.J. van Diest, Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod. Pathol. 23, 1029-1039 (2010)
24. G. Farshid, G. Cheetham, R. Davies, S. Moore, Z. Rudzki, Validation of the multiplex ligation-dependent probe amplification (MLPA) technique for the determination of HER2 gene amplification in breast cancer. Diagn. Mol. Pathol. 20, 11-17 (2011)
25. D.J. Bunyan, D.M. Eccles, J. Sillibourne, E. Wilkins, N.S. Thomas, J. Shea-Simonds et al., Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br. J. Cancer 91, 1155-1159 (2004)
26. O. Krijgsman, D. Israeli, H.F. van Essen, P.P. Eijk, M.L. Berens, C.H. Mellink et al., Detection limits of DNA copy number alterations in heterogeneous cell populations. Cell. Oncol. 36, 27-36 (2013)
27. E. Wiechec, J. Overgaard, E. Kjeldsen, L.L. Hansen, Chromosome 1q25.3 copy number alterations in primary breast cancers detected by multiplex ligation-dependent probe amplification and allelic imbalance assays and its comparison with fluorescent in situ hybridization assays. Cell. Oncol. 36, 113-120 (2013)
28. S. Elsheikh, A.R. Green, M.A. Aleskandarany, M. Grainge, C.E. Paish, M.B. Lambros et al., CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res. Treat. 109, 325-335 (2008)
29. R. Hui, J.R. Ball, R.D. Macmillan, F.S. Kenny, O.W. Prall, D.H. Campbell et al., EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 17, 1053-1059 (1998)
30. J. Bostner, M. Ahnstrom Waltersson, T. Fornander, L. Skoog, B. Nordenskjold, O. Stal, Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26, 6997-7005 (2007)
31. M.J. Duffy, M. Mullooly, N. O'Donovan, S. Sukor, J. Crown, A. Pierce et al., The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin. Proteomics 8, 9 (2011)
32. K. Chin, S. DeVries, J. Fridlyand, P.T. Spellman, R. Roydasgupta, W.L. Kuo et al., Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer cell 10, 529-541 (2006)
33. N. Nishikawa, M. Toyota, H. Suzuki, T. Honma, T. Fujikane, T. Ohmura et al., Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res. 67, 9649-9657 (2007)
34. G. Hu, R.A. Chong, Q. Yang, Y. Wei, M.A. Blanco, F. Li et al., MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer cell 15, 9-20 (2009)
35. I. Bieche, M. Olivi, C. Nogues, M. Vidaud, R. Lidereau, Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br. J. Cancer 86, 580-586 (2002)
36. C.M. Schlotter, U. Vogt, U. Bosse, B. Mersch, K. Wassmann, C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res. 5, R30-R36 (2003)
37. J.M. Bartlett, A.F. Munro, J.A. Dunn, C. McConkey, S. Jordan, C.J. Twelves et al., Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 11, 266-274 (2010)
38. M. Cuny, A. Kramar, F. Courjal, V. Johannsdottir, B. Iacopetta, H. Fontaine et al., Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res. 60, 1077-1083 (2000)
39. X. Cui, R. Schiff, G. Arpino, C.K. Osborne, A.V. Lee, Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol. 23, 7721-7735 (2005)
40. X. Cui, P. Zhang, W. Deng, S. Oesterreich, Y. Lu, G.B. Mills, A.V. Lee, Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol. Endocrinol. 17, 575-588 (2003)
41. V.J. Bardou, G. Arpino, R.M. Elledge, C.K. Osborne, G.M. Clark, Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21, 1973-1979 (2003)
42. R.M. Elledge, S. Green, R. Pugh, D.C. Allred, G.M. Clark, J. Hill et al., Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int. J. Cancer 89, 111-117 (2000)
43. E.A. Musgrove, C.E. Caldon, J. Barraclough, A. Stone, R.L. Sutherland, Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11, 558-572 (2011)
44. A.J. Butt, C.M. McNeil, E.A. Musgrove, R.L. Sutherland, Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr. Relat. Cancer 12(Suppl 1), S47-S59 (2005)
45. A. Arnold, A. Papanikolaou, Cyclin D1 in breast cancer pathogenesis. J. Clin. Oncol. 23, 4215-4224 (2005)
46. R.M. Zwijsen, R.S. Buckle, E.M. Hijmans, C.J. Loomans, R. Bernards, Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev. 12, 3488-3498 (1998)
47. R.M. Zwijsen, E. Wientjens, R. Klompmaker, J. van der Sman, R. Bernards, R.J. Michalides, CDK-independent activation of estrogen receptor by cyclin D1. Cell 88, 405-415 (1997)
48. P.G. Roy, N. Pratt, C.A. Purdie, L. Baker, A. Ashfield, P. Quinlan et al., High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Int. J. Cancer 127, 355-360 (2010)
49. S.P. Linke, T.M. Bremer, C.D. Herold, G. Sauter, C. Diamond, A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin. Cancer Res. 12, 1175-1183 (2006)
50. E.A. Musgrove, R.L. Sutherland, Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631-643 (2009)
51. O. Stal, A. Borg, M. Ferno, A.C. Kallstrom, P. Malmstrom, B. Nordenskjold et al., ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann. Oncol. 11, 1545-1550 (2000)
52. M. Ferrero-Pous, K. Hacene, C. Bouchet, V. Le Doussal, M. Tubiana-Hulin, F. Spyratos, Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin. Cancer Res. 6, 4745-4754 (2000)
53. A.S. Knoop, S.M. Bentzen, M.M. Nielsen, B.B. Rasmussen, C. Rose, Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J. Clin. Oncol. 19, 3376-3384 (2001)
54. D.A. Berry, H.B. Muss, A.D. Thor, L. Dressler, E.T. Liu, G. Broadwater et al., HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J. Clin. Oncol. 18, 3471-3479 (2000)
55. B. Ejlertsen, J. Aldridge, K.V. Nielsen, M.M. Regan, K.L. Henriksen, A.E. Lykkesfeldt et al., Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann. Oncol. 23, 1138-1144 (2012)
56. K.V. Nielsen, B. Ejlertsen, S. Muller, S. Moller, B.B. Rasmussen, E. Balslev et al., Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res. Treat. 127, 345-355 (2011)
57. F. Holst, P.R. Stahl, C. Ruiz, O. Hellwinkel, Z. Jehan, M. Wendland et al., Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat. Genet. 39, 655-660 (2007)
58. A. Ooi, M. Inokuchi, S. Harada, J. Inazawa, R. Tajiri, S.S. Kitamura et al., Gene amplification of ESR1 in breast cancers-fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J. Pathol. 227, 8-16 (2012)
59. C.B. Moelans, H.N. Monsuur, J.H. de Pinth, R.D. Radersma, R.A. de Weger, P.J. van Diest, ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Cell. Oncol. 34, 489-494 (2011)
60. C.B. Moelans, R.A. de Weger, M.T. van Blokland, E. van der Wall, P.J. van Diest, Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod. Pathol. 23, 62-70 (2010)
61. A.S. Knoop, H. Knudsen, E. Balslev, B.B. Rasmussen, J. Overgaard, K.V. Nielsen et al., Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 23, 7483-7490 (2005)
62. E. Arriola, S.M. Rodriguez-Pinilla, M.B. Lambros, R.L. Jones, M. James, K. Savage et al., Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res. Treat. 106, 181-189 (2007)
63. M.F. Press, G. Sauter, M. Buyse, L. Bernstein, W. Eiermann, T. Pienkowski et al., Alteration of topoisomerase II-alpha gene in human breast cancer and its association with responsiveness to anthracycline- based chemotherapy [Abstract]. In: Proceedings of 2007 Asco Annual Meeting; J. Clin. Oncol. 25, 524 (2007)